Sirnaomics has announced the establishment of a strategic partnership with EDIRNA Inc. ("EDIRNA"), providing an initial funding and an exclusive licensing of Sirnaomics proprietary delivery technologies for advancing EDIRNA's proprietary "Edit-to-Cure TherapeuticsTM" platform, targeting diseases with high unmet clinical need.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
6.3 HKD | -2.48% | -15.32% | -82.40% |
03/06 | Sirnaomics Medical, Finance Chiefs Step Down | MT |
20/05 | Sirnaomics' Strategy Chief Steps Down | MT |
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-82.40% | 70.01M | |
+18.72% | 125B | |
+14.19% | 108B | |
-4.93% | 24.21B | |
+3.23% | 22.78B | |
-10.44% | 17.96B | |
-41.74% | 16.43B | |
-13.31% | 16.37B | |
+2.44% | 13.58B | |
+27.89% | 11.66B |
- Stock Market
- Equities
- 2257 Stock
- News Sirnaomics Ltd.
- Sirnaomics Ltd. Establishes Strategic Partnership with Edirna Inc